Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood
; 141(9): 996-1006, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108341
2.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
3.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
4.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
N Engl J Med
; 381(7): 626-636, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166680
5.
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Lancet Oncol
; 22(3): 370-380, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587894
6.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Lancet Oncol
; 21(9): 1234-1243, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818466
7.
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Lancet Oncol
; 21(3): 358-372, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007138
8.
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply.
N Engl J Med
; 380(14): 1376-1377, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943346
9.
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Cancer Immunol Immunother
; 66(10): 1249-1264, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28712033
10.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.
Lancet Oncol
; 21(11): e516, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152307
11.
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
J Immunother Cancer
; 10(6)2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728875
12.
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.
J Thorac Oncol
; 17(1): 103-115, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34455067
13.
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Eur J Cancer
; 160: 1-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801354
14.
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
J Clin Oncol
; 40(13): 1428-1438, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030011
15.
Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Clin Pharmacol Drug Dev
; 10(9): 1054-1063, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33932130
16.
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Clin Cancer Res
; 27(16): 4500-4510, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108180
17.
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Eur J Cancer
; 135: 31-38, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534242
18.
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
J Immunother Cancer
; 8(2)2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361337
19.
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Nat Med
; 26(10): 1557-1563, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33020648
20.
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
Clin Cancer Res
; 26(11): 2466-2476, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32047001